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Nasopharyngeal carcinomaIn the present study, we investigated the roles and molecular mechanisms of miR-320a in human
nasopharyngeal carcinoma (NPC). miR-320a expression was strongly reduced in NPC tissues and cell
lines. Overexpression of miR-320a signiﬁcantly suppressed NPC cell growth, migration, invasion and
tumor growth in a xenograft mouse model. A luciferase reporter assay revealed that miR-320a could
directly bind to the 30 UTR of BMI-1. Overexpression of BMI-1 rescued miR-320a-mediated biological
function. BMI-1 expression was found to be up-regulated and inversely correlated with miR-320a
expression in NPC. Collectively, our data indicate that miR-320a plays a tumor suppressor role in
the development and progression of NPC and may be a novel therapeutic target against NPC.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nasopharyngeal carcinoma (NPC) is a malignant squamous cell
carcinoma arising from epithelial cells located in the nasopharynx,
which is a leading form of cancer in Southeast Asia and Middle
East/North Africa [1]. Moreover, the incidence of NPC in such
regions remains quite high. When treated with radiation therapy
and adjuvant chemotherapy, NPC responds well and the 5-year
overall survival rate is approximately 70% [2,3]. However, NPC
can invade local tissues easily and within 4 years, 30–40% of
patients will develop distant metastases with poor prognosis [4].
Therefore, an improved understanding of the molecular basis of
pathogenesis is needed for the development of more effective
therapies for NPC.
MicroRNAs (miRNAs) are evolutionarily conserved, small non-
coding RNAs that play regulatory roles by binding to the 30-
untranslated region (30-UTR) of target mRNAs in a sequence-spe-
ciﬁc manner [5,6]. miRNAs have the potential to inﬂuence almost
every cellular process, such as proliferation, apoptosis, differentia-
tion, invasion and metabolism [7,8]. Moreover, accumulating
evidence has shown that miRNAs play critical roles in the
regulation of cancer initiation and progression [9]. A variety ofmiRNAs have been found to be dysregulated in NPC, such as
miR-663, miR-144, miR-26a, miR-451 and miR-9 [10–14], which
function as oncogenes or tumor suppressors depending on their
targets. Human miR-320a has been reported to be involved in pro-
gression of several cancers [15–17], but its speciﬁc roles and mech-
anisms in NPC have not been well established.
In the present study, the expression levels of miR-320a were
found to be signiﬁcantly down-regulated in NPC tissues and cell
lines. NPC cell proliferation, migration, invasion and tumor growth
in the xenograft mouse model were all strongly suppressed when
miR-320a was overexpressed. Furthermore, BMI-1 was found to
be a direct target gene of miR-320a, and overexpression of BMI-1
could rescue miR-320a-induced biological functions. In addition,
a negative correlation between the expression of miR-320a and
BMI-1 was found in NPC specimens. Collectively, our data indicate
that miR-320a plays a tumor suppressor role in the development
and progression of NPC and may be a novel molecular therapeutic
target against NPC.
2. Materials and methods
2.1. Clinical specimens and cell culture
Sixteen primary NPC biopsy specimens and ten normal naso-
pharyngeal epithelial specimens were collected from patients at
the 88th Hospital of PLA at the time of surgery and immediately
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informed consent for the use of these clinical materials in research,
and the project was approved by the Institutional Ethics Commit-
tee. The human NPC cell lines CNE1, CNE2, C666-1, HONE1 and
SUNE1 were cultured in RPMI-1640 medium supplemented with
10% FBS. The nasopharyngeal epithelial cell line NP69 was cultured
in keratinocyte-SFM (Life Technologies, Inc., Grand Island, NY)
supplemented with bovine pituitary extract (BD Biosciences, San
Diego, CA) as described previously [12]. All cell lines were cultured
in a humidiﬁed incubator in an atmosphere of 5% (v/v) CO2 at
37 C.
2.2. RNA isolation and quantitative real-time polymerase chain
reaction (qPCR)
Total RNA was isolated from cell lines and tumor samples using
the miRVANA Kit (Ambion, Carlsbad, MA) according to the manu-
facturer’s protocols. Complementary DNA synthesis was per-
formed using the PrimeScript RT Reagent Kit (TaKaRa, Osaka,
Japan). miRNA was converted to cDNA using the TaqMan microR-
NA reverse transcription kit (Applied Biosystems, Foster City, CA).
The expression levels of miR-320a were determined using the Taq-
man miRNA assay kit (Applied Biosystems) according to the man-
ufacturer’s instructions, and calculated by normalization to the
signal for U6 expression using the 244Ct method. The expression
levels of BMI-1 (forward: 50-ACTGGAAAGTGACTCTGGGA-30;
reverse 50-TACTGGGGCTAGGCAAACAA-30) were evaluated using
SYBR green PCR master mix (Applied Biosystems) and normalized
to b-actin. All of the reactions were run in triplicate.
2.3. Western blotting
Cells were lysed in RIPA buffer containing protease inhibitor
cocktail (Calbiochem, La Jolla, CA). After electrophoresis on a 10%
SDS–PAGE gel, proteins were transferred onto polyvinylidene
diﬂuoride membranes. The membranes were blocked with 5% milk
and incubated with primary antibodies against BMI-1 and b-actin
(Abgent, San Diego, CA) at 4 C overnight. The corresponding
horseradish peroxidase (HRP)-conjugated secondary antibody
was added and incubated at room temperature for 1 h. Signals
were visualized after chemiluminescence reaction with HRP
substrate.
2.4. Lentivirus transduction
The lenti-viral system with EGFP expressing miR-320a (lenti-
miR-320a) and the negative control lenti-vector (lenti-NC) were
purchased from Genechem (Shanghai, China). The NPC cell lines
C666-1 and SUNE1 were infected with lenti-miR-320a or lenti-
NC according to the manufacturer’s protocol.
2.5. Plasmid construction
The plasmid pcDNA-BMI-1 was constructed by inserting the
BMI-1 CDS (Proteintech Group, Inc., Chicago, IL) into the
pcDNA3.1(+) vector (Life Technologies, Inc.) at BamH I and Xba I
sites. A 370 bp fragment of the BMI-1 30-UTR (position 1-370) con-
taining the predicted binding site of miR-320a was ampliﬁed by
PCR and cloned into pGL3 Basic vector (Promega, Madison, WI).
The corresponding mutant constructs were created by mutating
the seed region of the miR-320a-binding site using a site-directed
mutagenesis kit (SBS Genetech, Beijing, China). The constructs
were conﬁrmed by sequencing.2.6. Cell proliferation and colony formation assays
Cell proliferation was determined by MTT assay according to a
standard method as described previously [18]. In brief, infected
or transfected cells seeded into 96-well plates (2  103/well) were
stained at the indicated time points with 100 lL sterile MTT dye
for 4 h. The absorbance at 570 nm of each well was measured using
a microplate reader, with 655 nm as the reference wavelength. For
colony formation assay, 500 cells were seeded into each well of
6-well plates. After 10 days in culture, the cells were ﬁxed using
70% ethanol and stained with 1% crystal violet solution for
20 min to visualize colonies for counting.
2.7. In vitro migration and invasion assays
For the invasion assay, the transwell system (24 wells, 8 lm
pore size with poly-carbonate membrane) and Matrigel (BD Biosci-
ences) were used according to the manufacturer’s protocols. Ali-
quots of 1  105 cells were seeded into the upper chambers
precoated with Matrigel and cultured in serum-free RPMI-1640
medium. The lower compartment was ﬁlled with RPMI-1640 with
10% FBS as a chemoattractant. After incubation for 24 h, the cells
remaining in the upper chamber were removed, and the cells at
the bottom of the insert were ﬁxed, stained in 0.5% crystal violet
and counted under a microscope (Olympus Corp., Tokyo, Japan).
The results were averaged over three independent experiments.
For the migration assay, cells were seeded into the upper chambers
without a Matrigel coating. The rest of the assay was carried out in
the same way as the invasion assay.
2.8. Luciferase reporter assay
The luciferase reporter assay was performed as described previ-
ously [19]. In brief, the NPC cell lines C666-1 and SUNE1 were
transfected with 100 ng pGL3-BMI-1-30 UTR (WT/MUT) plasmid
and 1 ng pRL-TK vector (Promega) containing Renilla luciferase in
combination with miRNA (100 nM) using Lipofectamine 2000 (Life
Technologies, Inc.). Luciferase activity was measured 48 h after
transfection using the dual luciferase reporter assay kit (Promega)
according to the manufacturer’s protocol. All transfection experi-
ments were conducted in triplicate and repeated three times
independently.
2.9. In vivo tumor growth assay
The established lenti-NC and lenti-miR-320a cells (1  106)
were collected and injected subcutaneously into the right lateral
axilla region of BALB/c nude mice (6 mice per group). Tumor size
was measured every 3 days using vernier calipers. After 26 days,
mice were killed and tumors were dissected and weighed. Tumor
volumes were calculated using the formula: length width2  0.5.
Animal handling and experimental procedures were approved by
the Animal Experimental Ethics Committee of the 88th Hospital
of PLA.
2.10. Statistical analysis
All data are expressed as the means ± S.D. from at least 3 inde-
pendent experiments. The relationship between miR-320a expres-
sion and BMI-1 mRNA expression level was analyzed using
Spearman’s correlation. The statistical signiﬁcance of differences
between groups was evaluated using Student’s t-test and a P-value
less than 0.05 was considered statistically signiﬁcant.
Fig. 1. The levels of miR-320a in NPC tissues and cell lines. (A) Relative miR-320a expression was examined by qPCR in NPC specimens and normal nasopharyngeal epithelial
tissues. (B) Relative miR-320a expression in NPC cell lines. U6 was used as the endogenous control for miR-320a. Data are expressed as mean ± S.D. of three independent
experiments (⁄P < 0.05).
Fig. 2. Overexpression of miR-320a inhibits NPC cell proliferation in vitro and in vivo. C666-1 and SUNE1 cells infected with lentivirus encoding pre-miR-320a were used in
these studies. (A) Relative miR-320a expression was examined by qPCR. (B) Cell viability was examined by MTT assay. (C) Cell growth capacity was evaluated using the colony
formation assay. (D) Flank tumors were established in nude mice (6 mice per group) as described in materials and methods. Representative images of tumors are shown. (E)
Tumor volume was measured at the indicated days. (F) After 26 days, mice were killed, and tumor weight was calculated. Data are expressed as mean ± S.D. of three
independent experiments (⁄P < 0.05).
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Fig. 3. Overexpression of miR-320a suppresses NPC cell migration and invasion. (A) Migration and (B) invasion of C666-1 and SUNE1 cells stably overexpressing miR-320a
were evaluated using the Transwell migration and Matrigel invasion assay. Data are expressed as mean ± S.D. of three independent experiments (⁄P < 0.05).
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3.1. Levels of miR-320a are frequently lower in NPC cell lines and
tissues
First, we analyzed the expression patterns of miR-320a by
qRT-PCR in 16 NPC and 10 normal nasopharyngeal epithelial
specimens. The results showed that miR-320a was frequently
down-regulated in NPC tissues compared with normal nasopha-
ryngeal epithelial specimens (Fig. 1A). Moreover, the expression
levels of miR-320a were also decreased in all 5 NPC cell lines
examined, particularly in SUNE1 and C666-1, when compared with
the nasopharyngeal epithelial cell line NP69 (Fig. 1B).
3.2. Overexpression of miR-320a suppresses NPC cell proliferation
in vitro and in vivo
To explore whether miR-320a has functional effects on NPC cell
proliferation, we stably infected C666-1 and SUNE1 cells with len-
tivirus containing pre-miR-320a. The highly up-regulated expres-
sion of miR-320a was conﬁrmed by qPCR (Fig. 2A). MTT assay
showed that the proliferation rates of C666-1 and SUNE1 stably
overexpressing lenti-miR-320a were signiﬁcantly decreased when
compared with those of lenti-NC infected cells (Fig. 2B). Similar
results were also observed in the colony formation assay, suggest-
ing a proliferation-inhibiting role of miR-320a in NPC cells
(Fig. 2C). To further determine whether miR-320a was associated
with tumorigenesis, C666-1 cells stably overexpressing miR-320a
were injected into nude mice. As indicated in Fig. 2D and E, the
tumors in mice bearing lenti-miR-320a grew more slowly than
those from lenti-NC cells within 14 days after inoculation, and this
difference continued to increase until the endpoint of the test.
When the tumors were harvested, the average weight of the
tumors from the lenti-miR-320a group was also signiﬁcantly
reduced compared with that of the lenti-NC group (Fig. 2F). Takentogether, these results indicate that miR-320a inhibits NPC cell
proliferation in vitro, and suppresses tumorigenesis in vivo.
3.3. Overexpression of miR-320a reduces migration and invasion of
NPC cells
To study the contribution of miR-320a to NPC cell migration
and invasion, transwell migration and Matrigel invasion assays
were performed. As shown in Fig. 3A, when infected with lenti-
miR-320a, the cell migration capability of both C666-1 and SUNE1
cell lines was reduced signiﬁcantly. Their capacity for invasion was
also obviously reduced in both cell lines infected with lenti-
miR-320a compared with those infected with lenti-NC (Fig. 3B).
These results indicate that miR-320a reduces NPC cell migration
and invasion.
3.4. miR-320a directly targets BMI-1
To identify direct targets of miR-320a for regulating NPC cell
proliferation and invasion, the two most-used public bioinformatic
algorithms, TargetScan and miRanda, were used in combination. As
shown in Fig. 4A, BMI-1 (B lymphoma mouse Moloney leukemia
virus insertion region 1), a polycomb gene family member, is the-
oretically a potential target gene of miR-320a, and the predicted
binding site between miR-320a and BMI-1 30-UTR is also illus-
trated. Western blot analysis showed that the expression level of
BMI-1 was signiﬁcantly decreased in both C666-1 and SUNE1 cell
lines infected with lenti-miR-320a compared with those infected
with lenti-miR-NC (Fig. 4B). Consistently, qPCR identiﬁed reduced
expression of BMI-1 targeted by miR-320a (Fig. 4C). To further test
whether BMI-1 is a direct target of miR-320a, the 30-UTR fragments
of BMI-1 which contain a wild-type or mutant binding site of miR-
320a were subcloned into the luciferase reporter vector. As shown
in Fig. 4D, overexpression of miR-320a in both C666-1 and SUNE1
cell lines signiﬁcantly reduced the luciferase activity of BMI-1
Fig. 4. BMI-1 is a downstream target of miR-320a. (A) Sequence alignment of a putative miR-320a binding site in the 30-UTR of BMI-1 mRNA. BMI-1 protein (B) and mRNA
expression levels (C) were detected by Western blotting and qPCR, respectively. (D) Luciferase activity of the wild-type (WT) and the mutant (MUT) BMI-1 30-UTR reporter
constructs in the presence of miR-320a. Data are expressed as mean ± S.D. of three independent experiments (⁄P < 0.05).
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BMI-1 with a mutant 30-UTR. These results suggest that
miR-320a downregulates BMI-1 expression by directly targeting
its 30-UTR.
3.5. The tumor suppressor role of miR-320a is mediated by
downregulating BMI-1
To conﬁrm that the tumor suppressor role of miR-320a in NPC is
mediated by repressing the expression of BMI-1, we performed a
gain-of-function assay. C666-1 and SUNE1 cell lines stably over-
expressing miR-320a were transfected with pcDNA3.1-BMI-1,
which encoded the full-length coding sequence without the 30-
UTR region (Fig. 5A). As shown in Fig. 5B, the inhibitory role of
miR-320a in proliferation was rescued under the condition of BMI-
1 overexpression. Accordingly, similar results could be observed
when cell migration and invasion assays were carried out (Fig. 5C
and D). These results suggest that a tumor suppressor role of miR-
320a in NPC cells is mediated by downregulation of BMI-1.
3.6. BMI-1 is up-regulated in NPC specimens and inversely correlated
with miR-320a levels
We further examined the expression levels of BMI-1 in clinical
NPC specimens by qPCR. As shown in Fig. 6A, the average expressionof BMI-1was signiﬁcantly higher in NPC tissues (n = 16) than in nor-
mal nasopharyngeal tissues (n = 10). In addition, correlation analy-
sis revealed that miR-320a levels negatively correlated with levels
of BMI-1 in NPC tissues (r = 0.603, P = 0.013; Fig. 6B).
4. Discussion
Previous studies have shown that miR-320a is dysregulated in
several cancers and its potential function has also been partly
explored in several studies. For example, Zhang et al. found that
miR-320a is associated with liver metastasis in colorectal cancer
(CRC) and inhibits tumor invasion by targeting neuropilin 1 [16].
Zhao et al. showed similar results, in that miR-320a signiﬁcantly
suppressed CRC cell migration/invasion and induced G0/G1 growth
arrest in vitro and in vivo by targeting Rac1 [17]. More recently,
Shang and colleagues reported that miR-320a is downregulated in
human bladder transitional cell carcinoma specimens and that
overexpression of miR-320a inhibits invasion of T24 cells [20]. On
the other hand, Yao et al. found that the tumor suppressive role of
GNAI1 on hepatocellular carcinoma cell migration and invasion is
post-transcriptionally regulated by miR-320a/c/d [21], suggesting
that miR-320a exhibits oncogenic properties in this cancer. These
contradictory results suggest that miR-320a might be expressed in
a tissue-speciﬁc pattern and have cell content-dependent functions.
Liu et al. recently performed miRNA microarray analysis and the
Fig. 5. BMI-1 can reverse the suppressive effect of miR-320a. C666-1- and SUNE1-miR-320a cells were transfected with or without pcDNA3.1-BMI-1. (A) BMI-1 protein level
was determined using Western blotting. Overexpression of BMI-1 rescued the effects of miR-320a on NPC cell proliferation (B), migration (C) and invasion (D). Data are
expressed as mean ± S.D. of three independent experiments (⁄P < 0.05).
Fig. 6. BMI-1 expression is up-regulated in NPC tissues and negatively correlated with miR-320a expression. (A) The miR-320a expression levels in NPC specimens and
normal nasopharyngeal tissues were analyzed by qPCR. (B) Spearman’s correlation analysis of miR-320a and BMI-1 mRNA levels in NPC tissues (r = 0.603; P = 0.013). Data
are expressed as mean ± S.D. of three independent experiments (⁄P < 0.05).
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NPC relative to non-cancer nasopharyngitis tissues, suggesting that
miR-320 may play a role in NPC progression [22]. However, to date,
no functional evidence of miR-320a in NPC has been documented.
In this study, we found that the expression level of miR-320a
was signiﬁcantly reduced in NPC tissues and cell lines. Overexpres-
sion of miR-320a signiﬁcantly inhibited cell proliferation in both
C666-1 and SUNE1 cell lines. Furthermore, Transwell migration
and Matrigel invasion assay showed that miR-320a greatly sup-
presses cell migration and invasive capability. We also explored
the role of miR-320a in vivo using a xenograft mouse model and
found that tumorigenesis and tumor growth were strongly sup-
pressed when miR-320a was overexpressed. These data suggest a
tumor-inhibiting role of miR-320a in NPC cells both in vitro and
in vivo.The mechanism by which miR-320a exerts its inﬂuence on the
development of NPC was also investigated in this study. Public bio-
informatic algorithms predicted BMI-1 to be a theoretical target
gene of miR-320a. We found that miR-320a directly targeted the
30-UTR of BMI-1 mRNA and repressed its expression. Restoring
the expression of BMI-1 can reverse the suppressive effects of
miR-320a. In addition, we found a negative correlation between
the expression of miR-320a and BMI-1 clinically. These data sug-
gest that BMI-1 is a direct and functional target of miR-320a in
NPC cells.
BMI-1 is a member of the Polycomb Group (PcG) family, which is
overexpressed in various types of human cancer [23,24]. It also
plays an oncogenic role in the development and progression of
cancers, including pancreatic cancer, breast cancer, lung cancer,
and gliomas [25–29]. Song et al. showed that BMI-1 expression
3738 X. Qi et al. / FEBS Letters 588 (2014) 3732–3738was markedly up-regulated in pancreatic cancer cell lines and tis-
sues and that stable down-regulation of BMI-1 suppressed cell
growth, delayed the G1/S transition, and induced cell apoptosis
[26]. Guo et al. showed that BMI-1 promoted invasion and metas-
tasis, and its elevated expression was correlated with an advanced
stage of breast cancer [27]. It was previously reported that BMI-1
was overexpressed in NPC cell lines and that high BMI-1
expression positively correlated with poor prognosis of NPC
patients [30]. This result is consistent with our ﬁndings that
BMI-1 is a functional target of miR-320a.
Taken together, our ﬁndings suggest that miR-320a is down-
regulated in NPC, and functions as a novel tumor suppressor to
regulate the proliferation, migration, invasion and tumorigenicity
of NPC cells by targeting BMI-1. Therefore, miR-320a may be a
novel molecular therapeutic target for the treatment of NPC.
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